News and Trends 12 May 2022 The Top European Biotech Investments in April 2022 Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […] May 12, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2022 eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO The French startup creator eureKARE has set up a special purposes acquisition company (SPAC) with the ambition to merge multiple European contract development and manufacturing organizations into a heavyweight serving developers of gene therapies, protein drugs, and microbiome therapeutics. Over the last few years, record levels of funding have flowed into the biotech industry, particularly […] May 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 May 2022 Exosome Therapy: Borrowing from Nature’s Toolbox In just a few years, exosomes have started gaining recognition as a solution to deliver treatments safely and effectively, and as a new approach to regenerative medicine. For hundreds of millions of years, multicellular organisms have faced many of the same challenges that biotechnology is grappling with today: how best to shuttle biomolecules to and […] May 9, 2022 - 11 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 6 May 2022 Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast Tapping into the increasingly sophisticated market for meat alternatives, the Swedish synthetic biology startup Melt&Marble has raised €5M in seed financing to fund the development of a fermented fat ingredient that mimics the complex properties of beef fat. Companies are racing to enhance the flavor, melt, and mouthfeel of meat alternative products such as plant-based […] May 6, 2022 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2022 Amphista Lands Megadeals to Smash Cancer using Protein Degradation As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […] May 5, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2022 Tubulis Rides Investment Wave in ADCs with €60M Series B The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals. ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist […] May 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 2 May 2022 Chief Business Officers: Shedding Light on Biotech’s Dealmakers In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry. Stephanie Bewick began her career as an academic researcher before spending more […] May 2, 2022 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2022 Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics The Danish National Genome Center has teamed up with the UK firm Lifebit to improve the access and sharing of genomic data as the nation moves towards the adoption of personalized medicine. Personalized medicine is capturing the attention of healthcare authorities across the world. By harvesting genome sequences from patient populations, researchers can mine vast […] April 29, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2022 OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […] April 28, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2022 Cancer Research UK Deploys €700M to Foster Oncology Startups In a show of strength after an income squeeze during the Covid-19 pandemic, the charity Cancer Research UK has dedicated €711M (£600M) to setting up a new innovation arm and seed fund designed to speed up the commercialization of oncology innovation. For decades, Cancer Research UK (CRUK) has played a pivotal role in nurturing advances […] April 27, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2022 Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart muscle from damage during heart attacks. A sudden heart attack, also known as acute myocardial infarction, happens when the flow of blood to the heart […] April 25, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 25 Apr 2022 Cloud Computing Can Help Life Sciences Catch Up Before It’s Too Late Biotechnology has the power to tackle global threats such as pandemics and climate change, but antiquated experimental and data collection methods are holding it back. Guy Levy-Yurista, CEO of the experiment platform developer Synthace, explains how cloud computing could accelerate the efforts of biotech companies to solve the big problems. There is a sundial in […] April 25, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email